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ABSTRACT
Neuroblastoma, a tumor of the peripheral sympathetic nervous system, is the most frequent solid extra cranial tumor in children 
and is a major cause of death from neoplasia in infancy. Still little improvement in therapeutic options has been made, requiring a 
need for the development of new therapies. In our laboratory, we address still unsettled questions, which of mechanisms of action 
of DNA-damaging drugs both currently use for treatment of human neuroblastomas (doxorubicin, cis-platin, cyclophosphamide and 
etoposide) and another anticancer agent decreasing growth of neuroblastomas in vitro, ellipticine, are predominant mechanism(s) 
responsible for their antitumor action in neuroblastoma cell lines in vitro. Because hypoxia frequently occurs in tumors and strongly 
correlates with advanced disease and poor outcome caused by chemoresistance, the effects of hypoxia on efficiencies and mecha-
nisms of actions of these drugs in neuroblastomas are also investigated. Since the epigenetic structure of DNA and its lesions play a 
role in the origin of human neuroblastomas, pharmaceutical manipulation of the epigenome may offer other treatment options also 
for neuroblastomas. Therefore, the effects of histone deacetylase inhibitors on growth of neuroblastoma and combination of these 
compounds with doxorubicin, cis-platin, etoposide and ellipticine as well as mechanisms of such effects in human neuroblastona 
cell lines in vitro are also investigated. Such a study will increase our knowledge to explain the proper function of these drugs on the 
molecular level, which should be utilized for the development of new therapies for neuroblastomas. 
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i) neuroblastic or N-type: undifferentiated, round and 
small cells with scant cytoplasm; and ii) stromal or S-type: 
large hyaline, flattened and adherent differentiated cells. 
As neuroblastoma cells seem to have the capacity to dif-
ferentiate spontaneously in vivo and in vitro (Morgenstern 
et al., 2004), their heterogeneity could affect treatment 
outcome, in particular the response to apoptosis induced 
by chemotherapy. Neuroblastoma may regress spontane-
ously in infants, mature to benign ganglioneuromas in 
older children, or grow relentlessly and be rapidly fatal 
(Brodeur, 2003). Approximately 40% of all patients with 
neuroblastoma belong to the high-risk group (high-risk 
neuroblastoma), and therapeutic improvements in 
the past decade have not substantially improved their 
outlook in compared to  other pediatric malignancies 
(Westermann and Schwab, 2002). Prognosis of high-risk 
neuroblastomas is poor, because drug resistance arises 
Introduction
Neuroblastoma, a tumor of the peripheral sympathetic 
nervous system, is the most frequent solid extra cranial 
tumor in children and is a major cause of death from 
neoplasia in infancy (Maris and Mathay, 1999; Schwab, 
1999). These tumors are biologically heterogeneous, 
with cell populations differing in their genetic programs, 
maturation stage and malignant potential (Brodeur, 
2003). Neuroblastoma consists of two principal neoplastic 
cells (Voigt et al., 2000; Hopkins-Donaldson et al., 2002): 
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in the majority of those patients, initially responding to 
chemotherapy, in spite of intensive therapy including 
megatherapy with subsequent hematopoietic progenitor 
cell transplantation, biotherapy and immunotherapy 
(Brodeur, 2003). Treatment of older children with widely 
disseminated neuroblastoma remains one of the greatest 
challenges for pediatric oncologists. However, still little 
improvement in therapeutic options has been made in the 
last decade, requiring a need for the development of new 
therapies. 
Drug-resistance in neuroblastomas
Drug-resistance in neuroblastomas might be caused by 
multiple factors, including overexpression of the genes for 
the multidrug-resistance-associated protein (MRP) and 
mdr-1 gene-encoded P-170 glycoprotein (Pgp) (Bates et al., 
1991; Bader et al., 1999). High levels of MRP gene expres-
sion are frequently found in neuroblastoma resistant to 
chemotherapeutic agents and are proven to correlate with 
poor outcome in patients with neuroblastoma (Norris 
et al., 1996; Peaston et al., 2001), whereas the contribu-
tion of mdr1 gene expression to the biology of childhood 
neuroblastomas is still a matter of debate (Kurowski and 
Berthold, 1998, Kucerova et al., 2001; de Cremoux et al., 
2007). Drug-resistance could be also caused by changes 
in apoptotic pathways. For example, mutations in p53 
or overexpression of Bcl-2, two regulators of apoptosis, 
c o n t r i b u t e  t o  n e o p l a s t i c  t r a n s f o r m a t i o n  b y  b l o c k i n g  
apoptosis (Lara-Bohórquez et al., 2008). Protection of cell 
death by Bcl-2 does not require participation of another 
apoptotic regulator Bax, but it is most effective when 
Bcl-2 is in excess of Bax (Otter et al., 1998; Uccini et al., 
2006). Chemoresistance is usually not caused by a single 
mechanism, but it is complex phenomenon (Bedrnicek et 
al., 2005). Recent studies have provided a link between 
the malignant and drug-resistant phenotypes, indicating 
that in addition to the development of drug resistance, 
chemotherapy of tumors may cause various changes 
in their biological characteristics, including increased 
malignancy and metastatic potential (Emanuel et al., 
1999; Kotchetkov et al., 2005). 
Ellipticine as a promising drug for 
neuroblastoma treatment 
Even though currently used cytostatics, including cis-
platin, etoposide, doxorubicin, vincristine and cyclophos-
phamide (Maris et al., 2007) are effective for treatment of 
neuroblastomas, they failed in their actions for a variety 
of patients. Hence, in the past two decades, attempts have 
been made to improve outcomes in high-risk patients by 
delivering intensive induction therapy. Recently, we have 
suggested novel treatment of neuroblastomas, utilizing a 
drug targeting DNA, plant alkaloid ellipticine. We have 
found that treatment of human neuroblastoma IMR-32, 
UKF-NB-3 and UKF-NB-4 cell lines (Figure 1) with this 
agent resulted in strong inhibition of cell growth, followed 
by induction of apoptosis (Figure 2) (Poljaková et al., 
2008; 2009). These effects were associated with forma-
tion of two covalent ellipticine-derived DNA adducts, 
identical to those formed by the cytochrome P450- and 
peroxidase-mediated ellipticine metabolites, 13-hydroxy- 
and 12-hydroxyellipticine (Figure 3) (Stiborová et al., 
2001; 2004; 2007a). In addition, besides the formation of 
such covalent ellipticine-derived DNA adducts, participa-
tion of the mechanisms in ellipticine toxicity to neuro-
blastoma, such as intercalation into DNA (Auclair, 1987; 
Singh et al., 1994), and inhibition of DNA topoisomerase 
Figure 2. The induction of apoptosis in ellipticine-treated 
neuroblastoma UKF-NB-4 cells. The DNA fragmentation was 
assessed by gel electrophoresis. Cells were treated with vehicle 
and ellipticine for 48 h, and then the fragmentation of DNA was 
assessed by agarose gel electrophoresis. (Lane 1) marker; (lane 2) 
UKF-NB-4 cells treated with vehicle alone (DMSO); (lane 3) 0.1 μM 
ellipticine, (lane 4) 1 μM ellipticine, and (lane 5) 10 μM ellipticine 
[adapted from reference (Poljakova et al., 2009)].
Figure 1. Neuroblastoma cell lines UKF-NB-4 (200-fold magnifi  -
cation) [adapted from reference (Poljakova et al., 2009)].49
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II activity (Auclair, 1987; Monnot et al., 1991; Fossé et al., 
1992; Froelich-Ammon et al., 1995] that were found to 
be additional DNA-mediated mechanisms of ellipticine 
antitumor, mutagenic and cytotoxic activities [for a sum-
mary see (Stiborová et al., 2001; 2006; 2010)], cannot be 
excluded. Therefore, ellipticine and/or its more effective 
derivatives seem to be promising drugs for future clini-
cal applications (Poljaková et al., 2009). This suggestion, 
however, needs to be confirmed by further investigations 
including the in vivo studies. 
Hypoxia frequently occurs in tumors because of their 
fast growth and inadequate vascularisation. It strongly 
correlates with advanced disease and poor outcome 
caused by chemoresistance. The hypoxia inducible 
factor (HIF) is a transcription factor, which seems to be 
important for cells to adapt to hypoxia. Hypoxia-induced 
chemoresistance to cis-platin and doxorubicin in human 
non-small cell lung cancer cells is through the HIF path-
way and may be reversed by postransriptional blocking of 
this factor. (Song et al., 2006). However, even though this 
and other factors were suggested to influence cytostatic-
induced apoptosis of cancer cells and to contribute to 
induce chemoresistance of cells to drugs, their actual 
roles in neuroblastomas remain still to be investigated. 
In the case of the ellipticine toxic activity to neuroblas-
toma cells, hypoxic cell culture conditions resulted in a 
decrease in ellipticine toxicity to these cells. One of the 
reasons causing this effect might follow from a decrease 
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Figure 3. Scheme of the metabolism of ellipticine by peroxidases and human CYPs showing the characterized metabolites and those proposed 
to form DNA adducts. The compounds shown in brackets are the hypothetical electrophilic metabolites postulated as ultimate arylating spe-
cies or the postulated N²-deoxyguanosine adducts.50
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in formation of ellipticine-derived DNA adducts in neuro-
blastoma cells, but exact mechanisms of such effects still 
await further investigations (Poljaková et al., 2009). 
Most of the drugs shown to be toxic to neuroblasto-
mas and may be used for their treatment (doxorubicin, 
cisplatin, etoposide, cyclophosphamide and ellipticine) 
are known to be the DNA-damaging agents. Their effects 
include non-covalent DNA intercalation, inhibition of 
topoisomerase II, formation of covalent DNA adducts, 
DNA-DNA cross-links and/or free radical effects on 
DNA [for a summary see (Klener, 1996)]. The question, 
however, arises on the real contribution of these effects to 
overall cytotoxicity of these drugs to neuroblastoma cells. 
At the present time it is not known, whether these indi-
vidual effects synergize to contribute to antitumor and 
cytostatic activities of these drugs to neuroblastoma cells. 
Moreover, it is also not possible to demonstrate which of 
these effects predominate in their cytotoxic activities. 
Combination of DNA-damaging drugs 
and epigenetics-based therapy with 
histone deacetylase inhibitors may be a 
promising therapy for neuroblastomas 
The use of potent epigenetics-based therapy for cancer 
cells might restore the abnormally regulated epigenomes 
to a more normal state through epigenetic reprogramming 
(Witt et al., 2009). Thus, epigenetic therapy may be a prom-
ising and potent treatment for human neoplasia. Because 
the epigenetic structure of DNA and its lesions play a role 
in the origin of human neuroblastomas, pharmaceutical 
manipulation of the epigenome may offer other treatment 
options also for neuroblastomas (Furchert et al., 2007). 
Indeed, former studies demonstrated the cytotoxicity of 
a panel of histone deacetylases inhibitors to neuroblasto-
mas, resulting in growth inhibition of these tumor cells 
(Cinatl et al., 1996; Michaelis et al., 2004; 2007; Furchert 
et al., 2007). Histone deacetylases and histone acetyl 
transferases modify histone proteins and contribute to an 
epigenetic code recognized by proteins involved in regula-
tion of gene expression (Marks et al., 2003; 2004; Hooven, 
et al., 2005). In neoplastic cells, where overexpression of 
different histone deacetylases was frequently detected 
(for summary see, Bolden et al., 2006), the abundance 
of deacetylated histones is usually associated with DNA 
hypermethylation and gene silencing (Santini et al., 
2007). Treatment with histone deacetylase inhibitors 
induced the reactivation of growth regulatory genes and 
consequently apoptosis in these cells. One of the histone 
deacetylase inhibitors, valproic acid (Figure 4), inhibits 
growth and induces differentiation of human neuroblas-
toma cells in vitro at concentrations ranging from 0.5 to 2 
mM that have been achieved in human with no significant 
adverse effects (Cinatl et al., 1996; Hřebačková et al., 
2009). Ultrastructural features of valproic acid-treated 
cells were consistent with the neuronal type of differen-
tiation and are associated with decreased expression of 
N-myc oncoprotein and increased expression of neutral 
cell adhesion molecule in their membrane. In these cells 
valproic acid treatment synergized interferon-alpha lead-
ing to a massive accumulation of cells in G0/G1-phase. 
This drug also influences the resistance of neuroblastoma 
cells to several chemotherapeutics (Blaheta et al., 2007). 
Valproic acid reverts the enhanced adhesion properties 
of drug-resistant UKF-NB-2, UKF-NB-6 and SKNSH 
neuroblastoma cells accompanied by diminished N-myc 
and enhanced p73 protein levels (Blaheta et al., 2007). 
Therefore, this drug may provide an alternative approach 
to the treatment of drug-resistant neuroblastomas by 
blocking invasive processes (Blaheta et al., 2007). 
Recently, combination of histone deacetylase inhibi-
tors valproic acid and/or trichostatin A (Figure 4) with 
DNA methyltransferase inhibitor 5-azacytidine (Zhu 
and Otterson, 2003; Chai et al., 2008), or with anticancer 
drugs that act by targeting DNA, vepesid (VP-16), ellip-
ticine, doxorubicin, epirubicin, and cis-platin, enhances 
their efficacy in several tumour cells (Kim et al., 2003; 
Marchion et al., 2005a; 2005b; Catalano et al., 2006). Its 
effect on cytotoxic potential of drugs used for treatment 
of neuroblastomas has, however, not been evaluated. Our 
preliminary results suggest that the anticancer activity 
of ellipticine to neuroblastomas might be synergically 
increased by these histone deacetylase inhibitors. These 
preliminary data show that a higher sensitivity of neuro-
blastoma cells to ellipticine correlated with an increase 
in formation of covalent ellipticine-derived DNA adducts 
(unpublished data) that was found to be one of the most 
important DNA-damaging mechanisms of ellipticine 
action in neuroblastomas (Poljaková et al., 2009). However, 
the exact mechanisms of these features need further 
studies. Moreover, the effect of combination of valproic 
acid and trichostatin A with other DNA-damaging drugs 
used for neuroblastoma treatments (anthracyclines such 
as doxorubicin, platinum complexes, cyclophosphamide 
and etoposide) on growth of neuroblastoma cells and 
the mechanisms of such a drug combination have not 
yet been investigated. Hence, these subjects also await 
further examinations. 
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Figure 4. Valproic acid (A) and trichostatin A (B).51
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Conclusions
Most of the above mentioned phenomena, which have 
not been properly explained as yet, are addressed in the 
grant project of the Grant Agency of Czech Republic 
(P301/10/0356) solved in our laboratory. Namely, the 
questions which of DNA-damaging mechanisms of action 
(non-covalent DNA intercalation, covalent DNA adducts 
formation, DNA-DNA cross-links and DNA strand-breaks 
induced by inhibition of topoisomerase II and radical 
effects) both for drugs currently used for treatment of 
human neuroblastoma cancers (doxorubicin, platinum 
complexes, cyclophosphamide and etoposide) and another 
anticancer agent decreasing growth of neuroblastoma 
cells in vitro, ellipticine, are predominant mechanism(s) 
responsible for their antitumor action. Their effects in 
combination with histone deacetylase inhibitors such as 
valproic acid and/or trichostatin A and mechanisms of 
such effects are other questions that are also investigated. 
Such a study will increase our knowledge to explain the 
proper function of these drugs on the molecular level, 
which should be utilized for the development of new 
therapies for neuroblastomas. 
Because metabolism of these agents, leading either 
to covalent modification of DNA by them or to their 
detoxication, are dependent on expression and activities 
of enzymes biotransforming drugs such as cytochromes 
P450 and/or peroxidases for ellipticine (Stiborová et al., 
2001; 2003a; 2003b; 2004; 2006; 2007a; 2007b; 2008; 
2010), etoposide (van Schaik, 2008) or cyclophosphamide 
(Oesch-Bartlmowicz and Oesch, 2004; van Schaik, 2005; 
2008; Wang and Tompkins, 2008) and reductases such as 
NADPH:cytochrome P450 reductase, carbonyl reductase 
(secondary-alcohol:NADPH oxidoreductase) and/or 
NADPH:quinone oxidoreductase for doxorubicin (Merk 
and Jugert, 1991; Gavelova et al., 2008; Lal et al., 2010), 
investigation of their expression levels and activities will 
be another aim of our research. 
A successful solution of the above features seems to 
have unquestionable practical importance, as it could be 
utilized for enhancing efficiency of the studied drugs, both 
of those currently used for neuroblastoma treatment and a 
novel anticancer agent, ellipticine, utilizing their combine 
effects with inhibitors of histone deactylases. The results 
might, therefore, be utilized for the development of new 
therapies for neuroblastomas. In the case of ellipticine, 
the results will also be promising for ellipticine utilization 
in cytochrome P450- and/or peroxidase-mediated gene 
therapy and for preparation of such ellipticine derivatives 
that will be appropriate for tumor targeting.
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